ASLAN Pharma of Singapore Announces $34 Million C Funding

ASLAN Pharma, a Singapore oncology-focused biotech, raised $34 million in a Series C round. The company said the financing would pay for ten clinical trials of its four novel drugs. The funding was led by Accuron Technologies Limited, a wholly-owned subsidiary of Temasek Holdings, the sovereign wealth fund of Singapore. The latest funding doubles ASLAN's previous rounds, bringing total capital raised to $68 million. More details... Share this with colleagues: // //